New research reveals critical gaps in treatment for advanced non–small cell lung cancer (NSCLC), emphasizing the need for ...

Among young people born in 2008 to 2017, 15.6 million lifetime gastric cancer cases are expected globally, with more than three-quarters attributable to Helicob ...

The phase 3 FORTITUDE-101 trial, conducted with the support of Zai Lab, has been evaluating bemarituzumab plus mFOLFOX6 ...

Researchers say about three-quarters of gastric cancer cases worldwide are caused by the common bacteria Helicobacter pylori ...

Only a third of patients with advanced cancer had molecular testing to help guide the use of targeted therapies, a review of ...